Table 3.
Univariate and multivariate analyses for DFS among patients with trastuzumab
| Factor | Univariate | Multivariate | p-value | |
|---|---|---|---|---|
| p-value | HR | 95%CI | ||
| Age (≤40 vs. > 40) | < 0.001 | 3.907 | 1.551–9.840 | 0.004 |
| T stage | 0.417 | |||
|
(T2 vs. T1) (T3 vs. T1) |
||||
| pN stage | < 0.001 | |||
| (pN1 vs. pN0) | 2.930 | 0.832–10.320 | 0.094 | |
| (pN2–3 vs. pN0) | 9.478 | 3.026–29.681 | < 0.001 | |
| Grade (3 vs. 1–2) | 0.013 | 0.435 | ||
| HR (negative vs. positive) | 0.001 | 5.854 | 1.878–18.245 | 0.002 |
| Ki67 (≥30% vs. < 30%) | 0.574 | |||
| pre-NLR (high vs. low) | 0.003 | 2.917 | 1.055–8.062 | 0.039 |
| NC (yes vs. no) | 0.333 |
HR, hazard ratio; CI, confidence interval; NC, neoadjuvant chemotherapy; NLR, neutrophil/lymphocyte ratio; ALC, absolute lymphocyte count. Statistically significant factors are in bold font